BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K, Takahashi M, Arai Y. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 2013;118:16-22. [PMID: 23167460 DOI: 10.3109/03009734.2012.729104] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Yen YC, Hsu HL, Chang JH, Lin WC, Chang YC, Chang CL, Chow JM, Yuan KS, Wu ATH, Wu SY. Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment. Radiother Oncol 2018;129:52-60. [PMID: 29703499 DOI: 10.1016/j.radonc.2018.03.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
2 Qiu B, Zhao MF, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Dai S, Yao JN, Liu FQ. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension. World J Gastroenterol 2015; 21(43): 12439-12447 [PMID: 26604651 DOI: 10.3748/wjg.v21.i43.12439] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
3 Cheng AL, Amarapurkar D, Chao Y, Chen P, Geschwind J, Goh KL, Han K, Kudo M, Lee HC, Lee R, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan C, Tanwandee T, Teng G, Park J. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-83. [DOI: 10.1111/liv.12314] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
4 Tan X, Liu B. [Radiofrequency Ablation for Lung Ground-glass Nodule]. Zhongguo Fei Ai Za Zhi 2021;24:677-82. [PMID: 34696540 DOI: 10.3779/j.issn.1009-3419.2021.101.35] [Reference Citation Analysis]
5 Park C, Gwon DI, Chu HH, Kim JW, Kim JH, Ko GY. Correlation of tumor response on CT with pathologically proven necrosis in hepatocellular carcinoma treated by conventional transcatheter arterial chemoembolization: threshold value of intratumoral Lipiodol accumulation predicting tumor necrosis. Abdom Radiol (NY) 2021;46:3729-37. [PMID: 33141259 DOI: 10.1007/s00261-020-02845-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, Laberge JM, Kerlan RK, Fidelman N. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol. 2013;36:1336-1343. [PMID: 23864021 DOI: 10.1007/s00270-013-0698-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
7 Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baek SE, Chung YE, Park MS, Kim MJ, Rhee H, Kim SU. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. Gut Liver 2020;14:765-74. [PMID: 32050313 DOI: 10.5009/gnl19197] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
8 Lopez-Lopez V, Brusadin R, López-Conesa A, Capel A, Navarro-Barrios Á, Cayuela V, Lopez-Banet E, Garzón-Arana A, Parrilla-Paricio P, Robles-Campos R. Preoperative transarterial chemoembolization for laparoscopic liver resection in Child A cirrhotic patients with hepatocellular carcinoma. Langenbecks Arch Surg 2021;406:763-71. [PMID: 33411038 DOI: 10.1007/s00423-020-02056-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Patil V, Noronha V, Joshi A, Muddu Krishna V, Juvekar S, Pantvaidya G, Chaturvedi P, Chaukar D, Arya S, Patil A, Bhosale B, Dongre A, Dcruz AK, Prabhash K. Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy? ISRN Oncol 2013;2013:259154. [PMID: 24109521 DOI: 10.1155/2013/259154] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
10 Kielar A, Fowler KJ, Lewis S, Yaghmai V, Miller FH, Yarmohammadi H, Kim C, Chernyak V, Yokoo T, Meyer J, Newton I, Do RK. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 2018;43:218-30. [PMID: 28780679 DOI: 10.1007/s00261-017-1281-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 15.8] [Reference Citation Analysis]
11 Song S, Bai M, Li X, Gong S, Yang W, Lei C, Tian H, Si M, Hao X, Guo T. Early Predictive Value of Circulating Biomarkers for Sorafenib in Advanced Hepatocellular Carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35234564 DOI: 10.1080/14737159.2022.2049248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Henze J, Maintz D, Persigehl T. RECIST 1.1, irRECIST 1.1, and mRECIST: How to Do. Curr Radiol Rep 2016;4. [DOI: 10.1007/s40134-016-0178-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
13 Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M, Shao N, Khoshpouri P, Pandey P, Zarghampour M, Fouladi D, Liddell R, Anders RA, Kamel IR. Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. Eur Radiol. 2018;28:3032-3040. [PMID: 29383518 DOI: 10.1007/s00330-017-5198-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
14 Langenbach MC, Vogl TJ, Said G, Scholtz JE, Hammerstingl R, Gruber-Rouh T. Lipiodol as a Predictive Indicator for Therapy Response to Transarterial Chemoembolization of Hepatocellular Carcinoma. Cancer Biother Radiopharm 2021. [PMID: 33481646 DOI: 10.1089/cbr.2020.4137] [Reference Citation Analysis]
15 Wang X, Liang H, Lu Z. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. Minim Invasive Ther Allied Technol 2020;29:344-52. [PMID: 31375044 DOI: 10.1080/13645706.2019.1649286] [Reference Citation Analysis]
16 Choi MH, Park GE, Oh SN, Park MY, Rha SE, Lee YJ, Jung SE, Choi JI. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization. Acad Radiol 2018;25:1363-73. [PMID: 29555570 DOI: 10.1016/j.acra.2018.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
17 Zhang XR, Ouyang J, Huang JY. Quantitative evaluation of blood perfusion in hepatocellular carcinoma after transcatheter arterial chemoembolization by contrast-enhanced ultrasound. Shijie Huaren Xiaohua Zazhi 2019; 27(4): 276-281 [DOI: 10.11569/wcjd.v27.i4.276] [Reference Citation Analysis]
18 Zhang W, Liu C, Tan Y, Jiang L, Yan L, Yang J, Wen T. Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: A propensity-matching cohort study. International Journal of Surgery 2018;54:259-64. [DOI: 10.1016/j.ijsu.2018.03.051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
19 She WH, Cheung TT, Yau TC, Chan AC, Chok KS, Chu FS, Liu RK, Poon RT, Chan SC, Fan ST, Lo CM. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. Hepatobiliary Surg Nutr. 2014;3:185-193. [PMID: 25202695 DOI: 10.3978/j.issn.2304-3881.2014.07.09] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
20 Wu X, Chapiro J, Malhotra A. Cost-Effectiveness of Imaging Tumor Response Criteria in Hepatocellular Cancer After Transarterial Chemoembolization. J Am Coll Radiol 2021;18:927-34. [PMID: 33484726 DOI: 10.1016/j.jacr.2020.12.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Alvarez M, de Pina DR, Romeiro FG, Duarte SB, Miranda JR. Wavelet-based algorithm to the evaluation of contrasted hepatocellular carcinoma in CT-images after transarterial chemoembolization. Radiat Oncol 2014;9:166. [PMID: 25064234 DOI: 10.1186/1748-717X-9-166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
22 Piron L, Le Roy J, Cassinotto C, Delicque J, Belgour A, Allimant C, Beregi JP, Greffier J, Molinari N, Guiu B. Radiation Exposure During Transarterial Chemoembolization: Angio-CT Versus Cone-Beam CT. Cardiovasc Intervent Radiol 2019;42:1609-18. [PMID: 31222382 DOI: 10.1007/s00270-019-02269-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
23 Kostakoglu L, Nowakowski GS. End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma. PET Clin 2019;14:307-15. [PMID: 31084771 DOI: 10.1016/j.cpet.2019.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 Sakai K, Takeda H, Nishijima N, Orito E, Joko K, Uchida Y, Izumi N, Nishio K, Osaki Y. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. Oncotarget 2015;6:21636-44. [PMID: 26046304 DOI: 10.18632/oncotarget.4270] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
25 Lin YH, Hung SK, Chiou WY, Lee MS, Shen BJ, Chen LC, Liu DW, Tsai WT, Lin PH, Shih YT, Hsu FC, Tsai SJ, Chan MWY, Lin HY. Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report. Medicine (Baltimore). 2016;95:e4717. [PMID: 27559982 DOI: 10.1097/md.0000000000004717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
26 Reis SP, Sutphin PD, Singal AG, Grzybowski R, Fisher S, Ball C, Xi Y, Grewal S, Kalva SP. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma. J Comput Assist Tomogr 2017;41:289-93. [PMID: 27824665 DOI: 10.1097/RCT.0000000000000509] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
27 Patel T, Harnois D. Assessment of response to therapy in hepatocellular carcinoma. Ann Med 2014;46:130-7. [PMID: 24716738 DOI: 10.3109/07853890.2014.891355] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
28 Gregory J, Dioguardi Burgio M, Corrias G, Vilgrain V, Ronot M. Evaluation of liver tumour response by imaging. JHEP Rep 2020;2:100100. [PMID: 32514496 DOI: 10.1016/j.jhepr.2020.100100] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
29 Wang Y, He XH, Xu LC, Huang HZ, Li GD, Wang YH, Li WT, Wang GZ. CT-guided cryoablation for unresectable pelvic recurrent colorectal cancer: a retrospective study. Onco Targets Ther 2019;12:1379-87. [PMID: 30863104 DOI: 10.2147/OTT.S189897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
30 Mou W, Xue H, Tong H, Sun S, Zhang Z, Zhang C, Sun Q, Dong J, Wen X, Yan G, Tian Y. Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy. Oncol Lett 2014;7:2073-8. [PMID: 24932291 DOI: 10.3892/ol.2014.1988] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
31 Rattanasupar A, Chang A, Prateepchaiboon T, Pungpipattrakul N, Akarapatima K, Songjamrat A, Pakdeejit S, Prachayakul V, Piratvisuth T. Impact of alcohol consumption on treatment outcome of hepatocellular carcinoma patients with viral hepatitis who underwent transarterial chemoembolization . World J Hepatol 2022; 14(6): 1162-1172 [DOI: 10.4254/wjh.v14.i6.1162] [Reference Citation Analysis]
32 Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A, Harmath CB, Lewandowski RJ, Salem R, Yaghmai V. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology 2015;62:1111-21. [PMID: 25999236 DOI: 10.1002/hep.27915] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
33 Kim MN, Kim BK, Han K, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Review of Gastroenterology & Hepatology 2014;9:335-48. [DOI: 10.1586/17474124.2015.959929] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
34 Tovoli F, Renzulli M, Negrini G, Brocchi S, Ferrarini A, Andreone A, Benevento F, Golfieri R, Morselli-Labate AM, Mastroroberto M, Badea RI, Piscaglia F. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. Eur Radiol 2018;28:3611-20. [PMID: 29633000 DOI: 10.1007/s00330-018-5393-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
35 Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han K, Baek S, Kim HS, Kim SU, Park MS. Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. Liver Int 2018;38:1655-63. [DOI: 10.1111/liv.13731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
36 Peng Y, Liu F, Xu H, Wei Y, Li B. Is laparoscopic liver resection suitable for selected patients with BCLC stage B HCC? A propensity score-matched analysis. HPB (Oxford) 2020;22:595-602. [PMID: 31540884 DOI: 10.1016/j.hpb.2019.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, Han GH, Wang MQ, Liu RB, Lu LG, Ren ZG, Chen MS, Zeng ZC, Liang P, Liang CH, Chen M, Yan FH, Wang WP, Ji Y, Cheng WW, Dai CL, Jia WD, Li YM, Li YX, Liang J, Liu TS, Lv GY, Mao YL, Ren WX, Shi HC, Wang WT, Wang XY, Xing BC, Xu JM, Yang JY, Yang YF, Ye SL, Yin ZY, Zhang BH, Zhang SJ, Zhou WP, Zhu JY, Liu R, Shi YH, Xiao YS, Dai Z, Teng GJ, Cai JQ, Wang WL, Dong JH, Li Q, Shen F, Qin SK, Fan J. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer. 2018;7:235-260. [PMID: 30319983 DOI: 10.1159/000488035] [Cited by in Crossref: 186] [Cited by in F6Publishing: 196] [Article Influence: 46.5] [Reference Citation Analysis]
38 Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One 2015;10:e0133488. [PMID: 26230853 DOI: 10.1371/journal.pone.0133488] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 8.1] [Reference Citation Analysis]
39 Smith WH, Law AS, Hulkower M, McGee HM, Lehrer EJ, Schwartz M, Taouli B, Sung M, Buckstein M. The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma. Acta Oncol 2020;59:940-3. [PMID: 32441551 DOI: 10.1080/0284186X.2020.1769860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Qi F, Wang L, Huang P, Zhao Z, Yang B, Xia J. Time-series clustering of cytokine expression after transarterial chemoembolization in patients with hepatocellular carcinoma. Oncol Lett 2020;19:1175-86. [PMID: 31966047 DOI: 10.3892/ol.2019.11209] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Cho Y, Lee S, Park SJ. Effectiveness of intraprocedural dual-phase cone-beam computed tomography in detecting hepatocellular carcinoma and improving treatment outcomes following conventional transarterial chemoembolization. PLoS One 2021;16:e0245911. [PMID: 33513172 DOI: 10.1371/journal.pone.0245911] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Moschouris H, Malagari K, Papadaki MG, Kornezos I, Stamatiou K, Anagnostopoulos A, Chatzimichael K, Kelekis N. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization. Diagn Interv Radiol. 2014;20:136-142. [PMID: 24317334 DOI: 10.5152/dir.2013.13282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]